It is demonstrated that SMAD4 regulated 3D genome organization through its canonical transcription factor activity by directly binding chromatin, thereby suppressing lung tumorigenesis and revealing enhancer–promoter rewiring as a key mechanism driving lung tumorigenesis and a potential therapeutic vulnerability in SMAD4-deficient lung cancer.
Abstract
Dysregulation of three-dimensional (3D) genome architecture is a hallmark of cancer, yet the mechanisms by which its disruption drives tumorigenesis remain incompletely understood. Here, we demonstrated that SMAD4 regulated 3D genome organization through its canonical transcription factor activity by directly binding chromatin, thereby suppressing lung tumorigenesis. Hi-C analyses of human lung tumors identify SMAD4 as a potential regulator of 3D genome integrity. Using PTEN-deficient human bronchial epithelial cells and genetically engineered mouse models, we showed that SMAD4 loss induced widespread reorganization of chromatin compartments, topologically associating domain (TAD) boundaries, and chromatin loops, leading to oncogenic transcriptional rewiring during early tumorigenesis. Mechanistically, SMAD4 directly bound chromatin loops and spatially connected gene promoters with active or repressive regulatory elements to control transcription. Upon SMAD4 ablation, enhancer–promoter rewiring dysregulated critical oncogenic drivers, including ELF3. Functional manipulation of an SMAD4-regulated ELF3-associated chromatin loop altered ELF3 expression and cell survival both in vitro and in vivo. Collectively, our findings establish SMAD4 as a direct regulator of 3D genome architecture through classical transcription factor binding to chromatin loops and reveal enhancer–promoter rewiring as a key mechanism driving lung tumorigenesis and a potential therapeutic vulnerability in SMAD4-deficient lung cancer.
Three-dimensional (3D) chromatin architecture provides a spatial framework through which genomic sequences, epigenetic states, transcription factors, and distal regulatory elements are integrated to control cell type-specific gene expression. Increasing evidence suggests that disruption of this organization contributes...
Tian-Tian Liu, Song-Shan Jiang, Jing Wang et al.· Frontiers in Cell and Develo...· 0 citations
It is shown that aging reshapes chromatin architecture and gene regulation in murine naive CD4+ T cells, a quiescent T cell population essential for adaptive immunity, and a critical role for SATB1 is revealed in maintaining 3D genome integrity in naive T cells and the dysregulation of genome architecture contributes t...
Bao Wang, Lu-Zhang Ji, Q. Bian· Science Advances· 0 citations
Cancer is increasingly recognized as a disease of transcriptional dysregulation in which genetic alterations and epigenetic remodeling cooperate to reprogram gene regulatory networks that govern cellular identity, proliferation, differentiation, and therapeutic response. Enhancer–promoter interactions are an important...
L. Choppavarapu, Bakhtiyor Nosirov, Michael Kahn et al.· Cancers· 0 citations
This study uncovers a previously undescribed DCBLD2-centered regulatory cascade that promotes colorectal cancer initiation and progression and represents promising prognostic biomarkers and actionable therapeutic targets for colorectal cancer.
Tong Wu, Lan Shao, Xin Hu et al.· Molecular Biomedicine· 0 citations
A novel JNK-dependent UBR5-CDC73 axis is defined that acts as a molecular brake of the CDC73 positive feedback loop to orchestrate transcriptional programs, providing new mechanistic insights into CDC73 post-translational regulation in tumorigenesis and promising therapeutic targets for CDC73-dysregulated diseases.
Ding-Ji Li, Xin-Chen Wang, Hui-Gen Luo et al.· Oncogene· 0 citations
Oncogenic KRAS mutations (G12D/G13D) drive metabolic reprogramming in colorectal cancer (CRC), yet targetable downstream effectors remain poorly defined. Here, we identify enolase-phosphatase 1 (ENOPH1) as an essential transducer directly upregulated by the KRAS-MEK-ERK axis. ENOPH1 is markedly elevated in KRAS-mutant...
Xin Chen, Yi-Ren Su, Zhi-Zhan Ni et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.